Events Partner Content 3rd Chronic Kidney Disease Drug Development (CKD3) Summit Advance Therapeutics for Chronic Kidney Disease
News Otsuka has high hopes for its 'drug creation engine' acquisi... Otsuka is paying $430 million for a US clinical-stage biotech company it hopes will act as a ‘drug creation engine’ to accelerate its research into kidney diseases.
News EU approves AZ's potential blockbuster hyperkalaemia drug After manufacturing issues, AstraZeneca hopes for FDA nod soon.
News AZ signs kidney drug deal with Ionis for up to $330m Deal is result of six-year collaboration with AZ
News Agios mulls early FDA filing for sickle cell therapy Agios is planning to file its sickle cell disease candidate mitapivat with the FDA under the accelerated pathway within the next few months.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
